ReviewFrontiers in immunology2026
CGRP: the immune system's double agent - context-dependent roles in inflammation, resolution and cancer.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcitonin gene-related peptide (CGRP) is traditionally recognized as a key mediator of nociception and vasodilation. However, it also functions as a context-dependent immune "double agent," capable of both restraining inflammation and driving pathological responses. Here we discuss CGRP multifaceted roles in innate and adaptive immunity, inflammation, resolution, infection, autoimmunity, and cancer. In the innate immune response, CGRP predominantly exerts anti-inflammatory and tolerogenic effects on macrophages, mast cells, neutrophils, ILC2s, and NK cells, yet can promote pro-inflammatory signalling in acute high-DAMP (damage associated molecular patterns) settings. In adaptive immunity, it generally suppresses Th1 responses and induces CD8
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.